Results 191 to 200 of about 43,205 (262)

Pharmacokinetic and Pharmacodynamic Drug‐Drug Interactions Between Cofrogliptin and Metformin in Healthy Subjects: A Single‐Center, Single‐Arm, Phase I Study in China

open access: yesClinical Pharmacology in Drug Development, Volume 15, Issue 10, October 2026.
Abstract This single‐center, single‐arm, Phase I study evaluated drug–drug interactions (DDIs) between cofrogliptin and metformin in healthy Chinese subjects. Twenty‐two subjects sequentially received metformin monotherapy (Days 1–4), cofrogliptin monotherapy (Days 6–34), and combination therapy (Days 38–47).
Cheng Cui   +8 more
wiley   +1 more source

Increased dipeptidyl peptidase 4 in patients with concomitant transthyretin cardiac amyloidosis and severe aortic stenosis. [PDF]

open access: yesInt J Cardiol Heart Vasc
Holt MF   +11 more
europepmc   +1 more source

Harnessing Terminalia arjuna in Next Generation Phytomedicine: Cutting Edge Nutraceutical Trends Shaping Food and Health

open access: yesFood Science &Nutrition, Volume 14, Issue 10, October 2026.
This graphical abstract illustrates the complete translational pipeline of Terminalia arjuna in modern phytomedicine and functional food development. It is rich in key bioactive compounds like arjunolic acid, arjungenin, flavonoids, and tannins which serve as the foundation for the plant's versatile medicinal uses and offers broad therapeutic benefits ...
Ishani Banerjee   +5 more
wiley   +1 more source

Caution in handling switchers in pharmacoepidemiologic studies estimating treatment effects: the example of dipeptidyl peptidase-4 inhibitors and inflammatory bowel disease. [PDF]

open access: yesAm J Epidemiol
Wang T   +15 more
europepmc   +1 more source

Elevated endogenous glucagon‐like peptide‐1 as a novel Alzheimer's disease biomarker associated with neuroinflammation and Aβ pathology

open access: yesGeneral Psychiatry, Volume 39, Issue 5, October 2026.
ABSTRACT Background Alzheimer's disease (AD), a neurodegenerative disorder, is pathologically defined by the accumulation of amyloid‐β (Aβ) plaques, hyperphosphorylated tau tangles and sustained neuroinflammation. Glucagon‐like peptide‐1 (GLP‐1), originally characterised as an incretin hormone, is also expressed endogenously in the brain.
Jianping Li   +12 more
wiley   +1 more source

Increased Dipeptidyl Peptidase-4 Promotes Adipose Inflammation and Dysfunction in Mice Under Chronic Stress. [PDF]

open access: yesFASEB J
Zhang M   +10 more
europepmc   +1 more source

Associations Between Antidiabetic Pharmacotherapy and Hearing Thresholds in Adult Hearing‐Impaired Patients With Type 2 Diabetes

open access: yesPharmacology Research &Perspectives, Volume 14, Issue 5, October 2026.
ABSTRACT Type 2 diabetes mellitus (T2DM) has increasingly been identified as a risk factor for sensorineural hearing loss, whereas the association between different antidiabetic therapies and hearing thresholds remains poorly characterized. This retrospective observational study evaluated 240 patients with T2DM and 105 normoglycemic controls who ...
Francesco Martines   +8 more
wiley   +1 more source

Glucagon‐Like Peptide‐1 Agonists and Blood Pressure Regulation: Molecular Mechanisms and Cardiovascular Implications

open access: yesPharmacology Research &Perspectives, Volume 14, Issue 5, October 2026.
ABSTRACT Incretin effect helps in regulating glucose homeostasis and maintaining glycaemic control within the human body. This effect is achieved by the two naturally occurring incretin hormones: glucose‐dependent insulinotropic polypeptide (GIP) and glucagon‐like peptide‐1 (GLP‐1).
Nora H. J. Alharbi
wiley   +1 more source

Home - About - Disclaimer - Privacy